Where can you legally get Ozempic or Mounjaro in Malaysia?
From a registered doctor who has assessed you, either supplied by that doctor or dispensed by a licensed pharmacist on that doctor's prescription. Semaglutide (sold as Ozempic, Wegovy and Rybelsus), liraglutide (Saxenda) and tirzepatide (Mounjaro) are all Group B poisons on the Poisons List under the Poisons Act 1952.
The Act lets a registered doctor supply a Group B poison to his or her own patient, and lets a licensed pharmacist dispense one against a prescription. Selling or supplying it to the public any other way is an offence. The consumer leaflet for Mounjaro on the register of the National Pharmaceutical Regulatory Agency (NPRA) calls it an injectable prescription medicine.
Which brand is registered for what matters too. Ozempic (semaglutide) is registered for type 2 diabetes, Wegovy (semaglutide) for weight management, and Mounjaro (tirzepatide) for both. The article on how the GLP-1 medicines differ sets out the registrations. The choice between them, and the dose, are written into the prescription.
How do you check that a pen is registered?
Find the registration number on the pack. It begins with MAL, followed by eight digits and then letters. NPRA's registration guidance gives the first of those letters a meaning. A stands for a scheduled poison, the class these prescription-only pens belong to. X stands for a non-scheduled poison, N for a health supplement and T for a traditional medicine. Search NPRA's Product Search by product name or number, and compare the name, strength and registration holder on the screen with the box in your hand.
The Ministry also points to the FarmaTag hologram on registered packs, which can be checked in its MyUBAT app (FarmaChecker). Its guide to buying medicines online tells buyers to look for a MAL number with the letter X, T or N only. None of those letters marks a scheduled poison, and the guide advises against social media and overseas sellers.
Try it with the names people search. On 30 September 2026 the register lists Ozempic, Wegovy, Saxenda, Rybelsus and Mounjaro, and returns nothing for Zepbound, the US brand of tirzepatide, or for retatrutide. A search that finds nothing is an answer. A genuine batch number can still appear on a fake pack: WHO's 2024 alert on falsified Ozempic described a falsified batch that carried one. So the whole pack has to match, and the hologram has to be checked on the box in your hand.
The doctor can be checked as well. The Malaysian Medical Council's public register, MeRITS, shows whether a doctor is fully registered with a current practising certificate, and the guide to checking a doctor's registration walks through the steps.
What about fake and unregistered pens?
Fake Ozempic exists. In June 2024 WHO issued an alert on three falsified batches of Ozempic found in Brazil, the United Kingdom and the United States between October and December 2023, and noted rising reports of falsified semaglutide in every region since 2022. A falsified pen can hold too little of the medicine, contaminants, or an undeclared ingredient such as insulin.
In January 2026 the Malaysian Obesity Society warned about unregulated GLP-1 products sold through online platforms and social media, sometimes as "research peptides". They may be unregistered, made without good manufacturing practice, kept out of the cold chain, of uncertain purity, or a different substance from the label.
The Ministry's Pharmacy Enforcement Division is working the supply side. The Ministry told Sinar Daily that the division issued warning letters in 2025 over 48 social media advertisements involving Ozempic, Mounjaro and Saxenda. From January to July 2026 it carried out 30 raids on weight-loss products, 17 of them on online sales, with seizures worth RM477,142. By 28 August, 209 weight-loss advertisements had come down from e-commerce platforms in 2026. Selling an unregistered medicine is an offence under the Sale of Drugs Act 1952, the Ministry says.
Retatrutide: what is being sold as "Reta"?
Retatrutide is an experimental medicine in phase 3 trials. The Health Ministry said on 28 August 2026 that no regulator anywhere has approved it and that no product containing it was registered in Malaysia as of 17 August 2026. NPRA's register returned no result for it on 30 September 2026.
Its developer, Eli Lilly, has said it will file for approval with the US FDA in the first quarter of 2027. Trial results in the news describe supervised trials, and say nothing about a pen from a listing, which no regulator has evaluated. Sold as "Reta" or as a "pen kurus", such a pen is an unregistered product with unverified contents, and the Ministry advises against buying or using it.
What does buying online without a prescription skip?
A prescription starts with an assessment. Before a GLP-1 medicine is prescribed, a doctor asks about pregnancy plans, past pancreatitis or gallbladder disease, other medicines that can lower blood sugar, such as insulin or a sulphonylurea, and any operation or sedation on the calendar, because NPRA has warned that these medicines may raise the risk of aspiration under anaesthesia. What a doctor checks before prescribing sets out the list. A listing typically asks the buyer none of it.
It continues with a plan. The Malaysian obesity guideline calls for medical supervision and careful monitoring, with face-to-face review monthly for the first three months and at least every three months after, and says to stop the drug if the patient has not lost more than 5% of body weight after three months or if significant safety or tolerability problems appear. Most stomach side effects arrive while the dose is stepped up, which the article on weight-loss injection side effects covers. A pen bought from a listing usually comes with no one to run that schedule.
And it gives the next clinician someone to ask. NPRA's pancreatitis alert of 22 July 2026 asks clinicians to enquire about GLP-1 use in anyone with severe abdominal pain, because privately prescribed treatment may not appear in medical records. Someone who bought a pen from a listing has no prescriber to call. Severe, persistent abdominal pain that may spread to the back, especially with nausea and vomiting, needs urgent medical attention.
The pen is one part of the treatment. The assessment, the dose plan and the review are the rest. Which of the two medicines suits a person is a separate question: the explainer on tirzepatide and the head-to-head trials of semaglutide and tirzepatide describe the evidence, and an assessment decides.
